Mosaic ImmunoEngineering delays Form 10-K filing

Accepted by SEC EDGAR 03/31/2026 - 01:06 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Mosaic ImmunoEngineering, Inc. notified the SEC that it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 because additional time, resources and effort are required to complete financial close and reporting procedures.

The company states it expects to file the Form 10-K no later than the fifteenth calendar day following the prescribed due date.

Insights

Corporate Reporting Analyst

Routine late-filing notice citing additional time for close procedures; short extension sought.

The notice cites Rule 12b-25 relief and states the company requires more time, resources and effort to complete year-end financial reporting for the period ended December 31, 2025. The filing commits to submit the Form 10-K within the 15-calendar-day extension window.

Key dependencies are completion of close procedures and any required accountant exhibits; subsequent filings will show whether the extension resolved outstanding items.

Key Figures

Fiscal year end: December 31, 2025 Extension window: 15 calendar days Contact phone: 657-208-0890

3 metrics

Fiscal year end December 31, 2025 period covered by the delayed Form 10-K

Extension window 15 calendar days committed filing timeline under Rule 12b-25

Contact phone 657-208-0890 person to contact regarding the notification

Key Terms

Rule 12b-25, Form 10-K, prescribed due date

3 terms

Rule 12b-25 regulatory

"The subject report could not be filed without unreasonable effort or expense"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 10-K regulatory

"unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K"

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

prescribed due date regulatory

"no later than the fifteenth calendar day following the prescribed due date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Mosaic ImmunoEngineering (CPMV) file an NT 10-K?

The company filed an NT 10-K to notify the SEC it could not timely file its annual Form 10-K. It cites the need for additional time, resources and effort to finish financial close and reporting procedures for the year ended December 31, 2025.

When does Mosaic expect to file the delayed Form 10-K for CPMV?

Mosaic expects to file the Form 10-K no later than the fifteenth calendar day following the prescribed due date. This is the extension window allowed under Rule 12b-25 when a company needs limited additional time to complete reporting.

Does the NT 10-K indicate missing earnings or restatements for CPMV?

No earnings data or restatement is disclosed in the notice. The form states additional time is needed to complete close procedures; it does not assert any anticipated significant change in results for the fiscal year ended December 31, 2025.

Who can be contacted about Mosaic's late filing (CPMV)?

The contact provided is Steven King with telephone number 657-208-0890. That contact is listed for questions regarding the Rule 12b-25 notification and the company’s plan to file the Form 10-K within the 15-day extension.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check One):	☒  Form 10-K	☐  Form 20-F	☐  Form 11-K	☐  Form N-CSR
	☐  Form 10-Q	☐  Form 10-D	☐  Form N-CEN

For Period Ended: December 31, 2025

☐  Transition Report on Form 10-K		☐  Transition Report on Form 20-F
☐  Transition Report on Form 11-K		☐  Transition Report on Form 10-Q

For the Transition Period Ended: ________________________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Mosaic ImmunoEngineering, Inc.

Full Name of Registrant:

Former Name if Applicable

9114 Adams Avenue, #202

Address of Principal Executive Office (Street and Number)

Huntington Beach, CA 92646

City, State, Zip Code

PART II - RULES 12b-25 (b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

	(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof could not be filed within the prescribed time period.

Mosaic ImmunoEngineering, Inc., a Delaware corporation (the “Company”), was unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Form 10-K”) by the prescribed deadline because additional time, resources and effort are required to complete work related to the Company’s financial reporting and close procedures. The Company expects to file its Form 10-K as soon as possible, but no later than the fifteenth calendar day following the prescribed due date of the Form 10-K.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification:

Steven King		657		208-0890
(Name)		(Area Code)		(Telephone No.)

(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). ☒ Yes ☐ No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

Mosaic ImmunoEngineering, Inc. 

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: March 31, 2026 By: /s/  Steven King                          Title President and CEO

3